Naolys Expands Reach in India Through New Partnership

Strengthening Supply Chains for Sustainable Health

Naolys, a pioneer in living biotechnologies, has announced a strategic alliance with Greenflo Bioactives, a prominent Indian distributor. The partnership will bring Naolys’ Plant Cell and ExoCell® active ingredient lines to the Indian market. The deal, finalized late last month, marks the company’s third major international partnership after collaborations in South Korea and Southeast Asia.

The collaboration aims to give Indian formulators easier access to Naolys’ innovative products. By leveraging Greenflo’s established distribution network, Naolys hopes to accelerate the adoption of its living biotechnologies in health and wellness applications across the sub‑continent. The partnership also aligns with Naolys’ mission to make advanced living ingredients available worldwide, supporting sustainable health solutions.

Under the agreement, Greenflo Bioactives will handle the logistics, marketing, and sales of both the Plant Cell and ExoCell® ranges in India. This move is expected to streamline supply chains and reduce delivery times for local manufacturers. „We’re excited to bring these cutting‑edge ingredients to India,” said a Naolys spokesperson. „Greenflo’s expertise in the local market will help us reach a broader audience and foster innovation in the region.”

How Will Indian Formulators Benefit?

The Plant Cell line contains bio‑engineered plant extracts designed to support cellular health, while ExoCell® products harness engineered exosomes for targeted delivery of bioactive molecules. Both lines have already shown promise in clinical studies focused on skin rejuvenation, joint health, and immune support. By making them available in India, Naolys anticipates a surge in research and development projects that integrate living biotechnologies into consumer products.

Indian formulators will gain direct access to Naolys’ proprietary technology without the need for complex import procedures. Greenflo’s local presence means faster regulatory approvals and more efficient compliance with Indian standards. „We’re committed to simplifying the process for our partners,” said Greenflo’s CEO. „Our team will handle all regulatory paperwork, ensuring a smooth rollout of these advanced ingredients.”

The partnership also includes joint educational initiatives. Naolys and Greenflo plan to host webinars and workshops to train formulators on the science behind Plant Cell and ExoCell® products. This knowledge transfer is expected to spur innovation in cosmetics, nutraceuticals, and functional foods, positioning India as a key player in the global living biotechnologies market.

What Does This Mean for Consumers?

Consumers in India can look forward to a new generation of products that incorporate living ingredients for enhanced efficacy. The collaboration is anticipated to bring about healthier skin care lines, joint supplements, and immune boosters that are both scientifically validated and sustainably sourced. „Our goal is to make cutting‑edge science accessible to everyday consumers,” said the Naolys CEO. „By partnering with Greenflo, we’re taking a significant step toward that vision.”

The partnership also underscores a broader trend toward sustainability in the health industry. Both companies emphasize the environmental benefits of living biotechnologies, which require fewer resources and produce less waste compared to traditional synthesis methods. This alignment is likely to attract eco‑conscious consumers and investors alike.

Frequently Asked Questions

Q1: When will the Plant Cell and ExoCell® products become available in India? A1: The products are slated for launch in the first quarter of 2027, following final regulatory approvals and distribution setup.

Q2: Will the partnership affect pricing for Indian consumers? A2: While exact pricing will depend on local market conditions, both companies aim to keep the products competitively priced to encourage widespread adoption.

Q3: Are there plans to expand this partnership beyond distribution? A3: Yes, both parties are exploring joint research projects and co‑development of new formulations tailored to the Indian market.